These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 23847040)

  • 21. First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia.
    Odibo AO; Rada CC; Cahill AG; Goetzinger KR; Tuuli MG; Odibo L; Macones GA; England SK
    J Perinatol; 2013 Sep; 33(9):670-4. PubMed ID: 23558430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
    Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
    Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia.
    Gómez-Arriaga PI; Herraiz I; López-Jiménez EA; Escribano D; Denk B; Galindo A
    Ultrasound Obstet Gynecol; 2014 May; 43(5):525-32. PubMed ID: 24185845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
    Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
    Espinoza J; Romero R; Nien JK; Gomez R; Kusanovic JP; Gonçalves LF; Medina L; Edwin S; Hassan S; Carstens M; Gonzalez R
    Am J Obstet Gynecol; 2007 Apr; 196(4):326.e1-13. PubMed ID: 17403407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships of serum placental growth factor and soluble fms-like tyrosine kinase-1 with fetal and uterine artery Doppler indices in pre-eclampsia.
    Li J; Cai A; Yuan Q; Ding H; Zhao D
    Int J Gynaecol Obstet; 2019 May; 145(2):176-181. PubMed ID: 30801711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia.
    Bian Z; Shixia C; Duan T
    PLoS One; 2015; 10(4):e0124684. PubMed ID: 25906026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging new biomarkers of preeclampsia.
    Polsani S; Phipps E; Jim B
    Adv Chronic Kidney Dis; 2013 May; 20(3):271-9. PubMed ID: 23928393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics.
    Tarasevičienė V; Grybauskienė R; Mačiulevičienė R
    Medicina (Kaunas); 2016; 52(6):349-353. PubMed ID: 27940029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
    Myatt L; Clifton RG; Roberts JM; Spong CY; Wapner RJ; Thorp JM; Mercer BM; Peaceman AM; Ramin SM; Carpenter MW; Sciscione A; Tolosa JE; Saade G; Sorokin Y; Anderson GD;
    BJOG; 2013 Sep; 120(10):1183-91. PubMed ID: 23331974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
    Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
    Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of pre-eclampsia combining NGAL and other biochemical markers with Doppler in the first and/or second trimester of pregnancy. A pilot study.
    Karampas GA; Eleftheriades MI; Panoulis KC; Rizou MD; Haliassos AD; Metallinou DK; Mastorakos GP; Rizos DA
    Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():153-7. PubMed ID: 27599094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
    Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
    Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes.
    Holmes VA; Young IS; Patterson CC; Maresh MJ; Pearson DW; Walker JD; McCance DR;
    Diabetes Care; 2013 Nov; 36(11):3671-7. PubMed ID: 23920083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.
    Kusanovic JP; Romero R; Chaiworapongsa T; Erez O; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gotsch F; Edwin SS; Gomez R; Yeo L; Conde-Agudelo A; Hassan SS
    J Matern Fetal Neonatal Med; 2009 Nov; 22(11):1021-38. PubMed ID: 19900040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia.
    Triunfo S; Crovetto F; Crispi F; Rodriguez-Sureda V; Dominguez C; Nadal A; Peguero A; Gratacos E; Figueras F
    Placenta; 2016 Jun; 42():44-50. PubMed ID: 27238713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.
    Herraiz I; Simón E; Gómez-Arriaga PI; Quezada MS; García-Burguillo A; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2018 Jul; 13():279-285. PubMed ID: 30177066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.